Highlights from the Tuesday, Nov. 6 program include:
9:30 a.m. - 10:30 a.m.
* Capturing, Counting and Identifying CECs: A Potential Diagnostic Marker for Patients with Pulmonary Arterial Hypertension
Clinical Pharmacology, Poster Form 5
11:00 a.m. - 4:30 p.m.
* Philanthropic Activity: Rise Against Hunger
Exhibit Hall A/B, Aisle 200
11:30 a.m. - 12:30 p.m.
* Prevention of Cerebral Ischemia/Reperfusion Injury by Neutrophil-Derived Nanovesicles
Bioanalytics, Poster Forum 3
* Development and Evaluation of Bone-Targeting Nanoparticle (BTN) as a New Treatment of Bacterial Bone Infections
Formulation and Quality, Poster Forum 8
1:30 p.m. - 2:30 p.m.
* Development of a Chitosan-shRNA Nanoplex as a Universal Influenza Therapeutic
Preclinical Development, Poster Forum 1
* Continuous Manufacturing and the Role of Models in Implementing Continuous Manufacturing
Sharmista Chatterjee, FDA
Room 147 AB
* Development of Biologics: Making Affordable High Quality Medicines by Leveraging Technologies and Data Analytics
Vikram Sinha, Ph.D. Assoc. Vice President & Head, Quantitative Pharmacology & Pharmacometrics, Merck, Inc.
Room 146 C
* Development, Current Applications, and Future Utility of the Organ on a Chip Technology
Donald Ingber, M.D., Ph.D., Wyss Institute for Biologically Inspired Engineering at Harvard
Room 150 B
* Lessons Learned from 30+ Years of Attempts to Become a Formulation Scientist
Wim Jiskoot, Ph.D., Professor, Univ. Leiden
Room 146 A
* Mass Spec Technology
Nathan Yates, Ph.D., Associate Professor, Department of Cell Biology and Scientific Director of the Biomedical Mass Spectrometry Center, University of Pittsburgh
Room 151 B
* New and Upcoming Drug Modalities
Ray Deshaies, Ph.D., Senior Vice President, Discovery Research, Amgen, Inc.
Room 150 A
* Non-traditional Approaches to Bioequivalence & Application of Clinical Pharmacology to Minimize Barriers to Generic Drug Substitution
Kathleen Uhl, M.D., Director, Office of Generic Drugs, FDA/Center for Drug Evaluation and Research
Room 152 AB
* State of the Art and Future Perspectives on the Predictive Immunogenicity
Bernard Maillère, Ph.D., CEA
Room 151 A
* Strategies and Visions for Continuous Biologics Manufacturing from End to End
Joseph Shultz, Novartis Pharma AG
Room 145 AB
* Transforming the Patient Experience Through Long Acting Injectable/Implantable Formulations: New Opportunities and Technologies
Matthew Burke, Ph.D., GlaxoSmithKline
Room 146 B
The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 9,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Visit http://www.